X4 Pharmaceuticals, Inc.
XFOR
$4.02
$0.030.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -99.72M | -79.20M | -95.10M | -101.98M | 14.60M |
| Total Depreciation and Amortization | 1.02M | 1.28M | 1.33M | 1.37M | 1.21M |
| Total Amortization of Deferred Charges | 870.00K | 865.00K | 859.00K | 832.00K | 827.00K |
| Total Other Non-Cash Items | 6.69M | -5.99M | -3.28M | -1.57M | -123.61M |
| Change in Net Operating Assets | -1.71M | -2.58M | -6.90M | -7.95M | -2.70M |
| Cash from Operations | -92.85M | -85.62M | -103.09M | -109.30M | -109.67M |
| Capital Expenditure | -- | -- | -41.00K | -133.00K | -267.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 105.00M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.54M | 8.15M | -17.28M | -4.44M | -35.56M |
| Cash from Investing | 30.54M | 8.15M | -17.32M | -4.58M | 69.17M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 20.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 238.63M | 238.63M | 92.67M | 5.77M | 294.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 238.63M | 238.63M | 92.67M | 5.77M | 20.29M |
| Foreign Exchange rate Adjustments | 121.00K | 213.00K | -34.00K | 132.00K | -25.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 176.45M | 161.38M | -27.77M | -107.97M | -20.23M |